SkyePharma News

FOR IMMEDIATE RELEASE SkyePharma Announces Successful Completion of FlutiformTM EU Clinical Trial Programme LONDON, UK, 2 November, 2009 - SkyePharma PLC today announces that its development and marketing partner Mundipharma International Corporation Limited has successfully completed the final Phase III clinical study for the European development ...

Flutiform U.S. Filing Update LONDON, UK, 1 September 2009 - SkyePharma PLC today provides an update following a meeting held with the US Food and Drug Administration to discuss the previously announced potential review issues in respect of the New Drug Application for its lead development product, Flutiform , an investigational treatment for ...

FDA Calendar Updates: Par Pharma , Watson Pharma , NeurogesX , And Trinity Biotech Trinity Biotech awaiting two responses from FDA Published on June 10, 2009 by Mike Havrilla, BioMedReports LOS ANGELES, CA Below is a summary of updates to the BioMedReports.com FDA Calendar , which includes a database of over 200 entries.

SkyePharma PLC today announces that the New Drug Application for its lead development product, Flutiform , an investigational treatment for persistent asthma in patients 12 years of age and older, has been accepted for review by the US Food and Drug Administration .

Appointment of New Non-Executive Director LONDON, UK, 15 May, 2009 - SkyePharma PLC today announces that it will appoint a new Non-Executive Director, Dr Thomas Werner, to the Board with effect from 16 May 2009.